相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Korro Bio nominated KRRO-121 as a development candidate for treating hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, representing potential first-in-class therapy for two diseases with over $1 billion market opportunities each. - The company secured an oversubscribed $85 million private placement led by Venrock Healthcare Capital Partners, extending cash runway into the second half of 2028 to support clinical development milestones. - KRRO-121 utilizes RNA editing to stabilize glutamine synthase protein in the liver, offering potential advantages over current treatments that require multiple daily doses and cause significant side effects. - The company advanced its GalNAc-conjugated oligonucleotide program for alpha-1 antitrypsin deficiency, achieving over 90% in vivo RNA editing and plans to nominate a development candidate in Q2 2026.
- GSK has returned global rights to WVE-006, the most advanced RNA editing medicine in clinical testing, to Wave Life Sciences after underwhelming Phase Ib/IIa results in alpha-1 antitrypsin deficiency. - The September 2024 trial data showed 11.9uM of alpha-1 antitrypsin protein levels with 200-mg dosing, falling just short of the 12uM threshold expected by analysts. - Wave plans to accelerate regulatory submissions and seek FDA guidance on accelerated approval pathways, with additional data from higher doses expected in Q1 2026. - The broader GSK-Wave collaboration continues with up to $2.8 billion in potential milestones across eight preclinical programs using Wave's PRISM platform.
- Korro Bio's lead RNA editing therapy KRRO-110 for alpha-1 antitrypsin deficiency failed to produce functional protein at expected levels in early clinical testing. - The company is abandoning its lead program and laying off 34% of staff while shifting to a new delivery approach using sugar molecules. - The setback leaves Korro behind competitors Wave Life Sciences and Airna in the RNA editing space for AATD treatment. - Korro's research collaboration with Novo Nordisk for cardiometabolic diseases has been paused for 12 months to reassess the program.
- Korro Bio's KRRO-110 successfully produced functional M-AAT protein in Alpha-1 Antitrypsin Deficiency patients but failed to reach the protective threshold of 11 µM needed for therapeutic benefit. - The company is pivoting to a GalNAc-conjugated delivery system for AATD treatment, with development candidate nomination expected in the first half of 2026. - Korro nominated KRRO-121, a new RNA editing candidate targeting hyperammonemia in urea cycle disorders and hepatic encephalopathy patients. - The company implemented a 34% workforce reduction to extend cash runway into the second half of 2027 while focusing resources on liver-targeted programs.
- Wave Life Sciences' experimental RNA editing medicine WVE-006 successfully helped patients with alpha-1 antitrypsin deficiency produce therapeutically relevant levels of a critical protein their bodies cannot make. - The therapy achieved total AAT protein levels of 11.9-12.8 micromolars across different dosing regimens, meeting regulatory thresholds for approval while demonstrating no serious adverse events. - Despite the clinical success, Wave shares dropped nearly 20% as the results fell slightly short of heightened investor expectations for protein expression levels. - The findings validate RNA editing as a viable therapeutic approach and may benefit other companies developing similar treatments, including Korro Bio and Beam Therapeutics.
- Korro Bio has received orphan drug designation from the European Medicines Agency for KRRO-110, an investigational RNA editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). - The designation follows a similar FDA orphan drug designation granted in March 2025, highlighting the urgent medical need for innovative treatments in this rare genetic disorder. - KRRO-110 is currently being evaluated in the Phase 1/2a REWRITE clinical study with interim data expected in the second half of 2025. - The therapy represents the first RNA editing oligonucleotide from Korro's proprietary OPERA platform, designed to restore normal protein function by editing defective RNA.
- Wave Life Sciences achieves first-ever RNA editing results in humans for alpha-1 antitrypsin deficiency, demonstrating therapeutic protein level increases with a single dose treatment. - RNA editing emerges as a potentially safer alternative to DNA editing, with companies like Ascidian Therapeutics and Korro Bio advancing clinical trials for rare genetic disorders. - The field has evolved significantly over the past decade, with new editing capabilities and delivery methods opening potential treatment opportunities for over 10 million patients.
• Korro Bio has received approval to begin a Phase I/IIa trial in Australia for KRRO-110, an RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). • The REWRITE trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110 in healthy adults and AATD patients with the PiZZ genotype. • KRRO-110 leverages Korro's OPERA platform to correct the disease-causing mutation in the SERPINA1 gene, potentially restoring normal AAT protein secretion. • Interim data from the trial is expected in the second half of 2025, with study completion anticipated in 2026.
• Wave Life Sciences pioneered clinical RNA editing, treating alpha-1 antitrypsin deficiency (AATD) by correcting mRNA mutations, offering a novel therapeutic approach. • RNA editing, utilizing ADAR enzymes and guide RNAs, allows for temporary and reversible modifications, reducing risks associated with permanent DNA alterations. • Companies like Korro Bio and Ascidian Therapeutics are expanding RNA editing applications to target diseases like Parkinson’s, ABCA4 retinopathy, and certain cancers. • Challenges remain in RNA editing, including improving specificity, managing transient effects, and enhancing delivery methods for broader clinical applications.
• Current AATD treatment, augmentation therapy, involves weekly infusions but doesn't reverse lung or liver damage, spurring the development of novel therapies. • Fazirsiran, an RNAi therapy by Arrowhead and Takeda, shows promise in reducing Z-AAT levels in Phase II trials, with Phase III trials underway for AATD-associated liver disease. • Beam Therapeutics is exploring BEAM-302, a liver-targeting base editing therapy, while Wave Life Sciences, AIRNA, and Korro Bio are advancing RNA-editing oligonucleotides for AATD. • With multiple investigational treatments showing promise, augmentation therapy could become obsolete within the next decade, potentially transforming AATD treatment.
